Metagonomic sequencing has helped researchers learn more about respiratory disease pathogens because the process canprovide ...

Two recombinant baculoviruses were produced in order to obtain a bovine viral diarrhea virus (BVDV) immunogen: AcNPV/E2 expressing E2 glycoprotein, and AcNPV/E0E1E2 expressing the polyprotein region ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Of patients with PIV-associated ARIs, 32.8% were positive for PIV-1, 15.5% for PIV-2, 40.3% for PIV-3, and 11.4% for PIV-4. In patients hospitalized for ARI due to other respiratory viruses, ...

Researchers from Purdue University and the U.S. Centers for Disease Control and Prevention have recently developed a novel influenza vaccine candidate that uses a bovine adenoviral (BAd) vector to ...

FDA Approves Merck’s Enflonsia for RSV Prevention in Infants: Enflonsia (clesrovimab-cfor) is a long-acting monoclonal antibody approved to prevent respiratory syncytial virus (RSV) lower respiratory ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA (clesrovimab-cfor) is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial ...

U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV ...